ulcerative colitis

[Acta Pharmacologica Sinica] Scientists demonstrated that GPR84 was highly upregulated in inflamed colon tissues of active ulcerative colitis patients and dextran sulfate sodium-induced colitis mice.

[MRM Health] MRM Health announced that the first patient received MH002 in a Phase Ib/IIa multi-center clinical trial in mild-to-moderate ulcerative colitis.

[Cellular & Molecular Immunology] Investigators showed that loss of ovarian tumor deubiquitinase 1 (OTUD1) in mice contributed to the pathogenesis of dextran sulfate sodium-induced colitis via excessive release of proinflammatory cytokines

[Nature Reviews Gastroenterology & Hepatology] Scentists present the state of the art on the most recently identified pathogenic mechanisms of this serious inflammatory bowel disease-related complication, focusing on possible targets of antifibrotic therapies, management strategies, and factors that might predict fibrosis progression or response to treatment.

[Gut] The authors used high-resolution endoscopy and colon tissue samples of active ulcerative colitis as well as experimental models of physical and chemical mucosal damage in mice deficient for peptidyl-arginine deiminase-4, gnotobiotic mice and controls.

[Bristol Myers Squibb] Bristol Myers Squibb announced the European Commission has granted a Marketing Authorization for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.